The pet cancer therapeutics include chemotherapy drugs, targeted therapies, combination therapies, and immunotherapy vaccines, which are commonly recommended by the veterinary doctors. The drugs are mostly recommended to treat various conditions such as lymphoma, mast cell tumors, fibrosarcoma, hemangiosarcoma, and others. Currently, a wide range of formulations are available in the global market for the treatment of pet cancers, which can be administered in the form of tablets, injections or can be applied topically. Thus, the large variety of treatment options has made it easy for the pets to receive effective cancer treatment suitable to curb the condition.
Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/1284
The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2017, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.
Increasing R&D initiatives for cancer management to augment market growth
Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global pet cancer therapeutics market in near future. For instance, in 2017, Animal Cancer Foundation (ACF) received a US$ 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which aimed to study similarities between naturally occurring cancers in people and pets and find effective treatment in both species. Also, in 2016, the Petco Foundation and Blue Buffalo Foundation invested US$ 2.35 million to support pet cancer research and treatment, as it represents a major cause of illness and premature death in affected species worldwide. Moreover, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to create a biobank of dog tumors for providing insights on cancer cure through research, in order to develop the most effective cancer therapy. Furthermore, organizations such as Animal Cancer Foundation, Petco Foundation, Veterinary Cancer Society, and PetCure Oncology are conducting oncology research such as canine cancer genome project to understand the genetic makeup of cancer tumors in animals, in order to discover targeted drug therapies with least toxic doses. However, increasing adoption of alternative treatment methods such as herbal medications, homeopathy and adverse effects such as diarrhea, musculoskeletal disorder, anorexia and high cost associated with pet cancer treatment are the factors restraining the market growth.
Increasing incidence and remission rates of pet cancers to accelerate the market growth
Increasing prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the pet cancer therapeutics market growth during the forecast period. According to the study by Fetch a Cure, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer. According to the study published by Animal Cancer Foundation, 2017, approximately around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing number of relapsed cancer rates and the availability of relapsed/ refractory therapeutics integrated with veterinarian recommendation is expected to additionally generate the revenue for the market players. According to the study by petMD, LLC, 2015, about 95% of dogs treated for lymphoma with chemotherapy protocols and conventional treatments are expected to experience disease relapse or remission. The duration of remission is less than 15 months in 50% of dog species. In 2017, a novel chemotherapy drug named Tanovea-CA1 (rabacfosadine for injection), manufactured by VedDC, Inc. was conditionally approved by the FDA as a first line treatment for dogs to treat relapsed/refractory lymphoma and canine lymphoma. The conditional approval of drug allows manufacturer to legally sell Tanovea-CA1, before proving it meets the substantial evidence standard of effectiveness for full approval.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/1284
The major players operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.